Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Xbrane Biopharma AB ROE % Related Terms
Xbrane Biopharma AB ROE % Historical Data
* Premium members only.
The historical data trend for Xbrane Biopharma AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xbrane Biopharma AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xbrane Biopharma AB ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's ROE % distribution charts can be found below:
* The bar in red indicates where Xbrane Biopharma AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Xbrane Biopharma AB (STU:7XB0) has a ROE % of -8.31% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Xbrane Biopharma AB and its competitors. According to the industry distribution chart, Xbrane Biopharma AB ranks #417 out of 1250 companies in the Biotechnology industry, placing it in the top 33.4%.
Is Xbrane Biopharma AB's ROE % too high?
Xbrane Biopharma AB's current ROE % is -8.31%. Based on the distribution chart, Xbrane Biopharma AB ranks #417 out of 1250 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xbrane Biopharma AB has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xbrane Biopharma AB ranks #417 out of 1250 companies for ROE %. This puts Xbrane Biopharma AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current ROE % is -8.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (STU:7XB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.51, compared to a current price of €0.75 — trading 47.1% above its estimated fair value. The current ROE % is -8.31%. Xbrane Biopharma AB's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Xbrane Biopharma AB (STU:7XB0), the current ROE % is -8.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xbrane Biopharma AB (STU:7XB0) Overvalued in 2026?
Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued.
The current stock price of €0.75 is trading 47.1% above its estimated GF Value™ of €0.51.
GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.
Key valuation signals for STU:7XB0:
ROE %: -8.31%
GF Value™: €0.51 vs. price of €0.75 (47.1% above fair value)
No single metric tells the full story. See the STU:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
51GF Score
Get the complete analysis for STU:7XB0
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7XB0 has been successfully added to your 
